Active approach to prostate cancer detection – what is reasonable and what may cause harm


Authors: R. Wasserbauer
Published in: Urol List 2014; 12(2): 19-28

Overview

Active approach to prostate cancer detection – what is reasonable and what may cause harm

Despite the continuously improving diagnostics, prostate cancer represents the second most common cause of death from malignancy in men in the Czech Republic. Beginning in the 1980´s the first attempts of systematic screening were made by introducing regular check-ups using digital rectal examination and ultrasound screening, then in the 1990´s prostate specific antigen (PSA) appeared on stage, which meant a real breakthrough in the early detection of prostate cancer. Currently screening is routinely performed using rectal examination, PSA test supplemented by determination of free PSA and prostate biopsy, when indicated. The aim of this work is to present a basic overview of current pos­sibilities of screening and early detection of prostate cancer.

Key words:
prostate cancer, prostate specific antigen, prostate biopsy, screening


Sources

1. Novotvary 2010 ČR. Ústav zdravotnických informací a statistiky ČR. [online]. Dostupné z: http:/ / www.uzis.cz/ system/ files/ novot2010.pdf.

2. Gosselaar C, Roobol MJ, Roemeling S et al. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2008; 54(3): 581– 588. doi: 10.1016/ j.eur­uro.2008.03.104.

3. Dvořáček J, Babjuk M et al. Onkourologie. Praha: Galén 2005: 261– 300.

4. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate‑ specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279(19): 1542– 1547.

5. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277(18): 1452– 1455.

6. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate‑ specific antigen levels in men with and without prostate disease. JAMA 1992; 267(16): 2215– 2220.

7. Carter HB, Pearson JD, Metter EJ. Longitudinal evaluation of prostate‑ specific antigen levels in men with and without prostate disease. JAMA 1992; 267(16): 2215– 2220.

8. Ramirez ML, Nelson EC, Devere White RW et al. Current applications for prostate‑ specific antigen doubling time. Eur Urol 2008; 54(2): 291– 300. doi: 10.1016/ j.eururo.2008.04.003.

9. Vickers AJ, Savage C, O’Brien MF et al. Systematic review of pretreatment prostate‑ specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27(3): 398– 403. doi: 10.1200/ JCO.2008.18.1685.

10. Jansen FH, van Schaik RH, Kurstjens J et al. Prostate‑ specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves dia­gnostic accuracy in prostate cancer detection. Eur Urol 2010; 57(6): 921– 927. doi: 10.1016/ j.eur­uro.2010.02.003.

11. Vlaeminck‑ Guillem V, Ruffion A, Andre J. Value of urinary PCA3 test for prostate cancer dia­gnosis. Prog Urol 2008; 18(5): 259– 265. doi: 10.1016/ j.purol.2008.03.029.

12. Auprich M, Bjartell A, Chun FK et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011; 60(5): 1045– 1054. doi: 10.1016/ j.eururo.2011.08.003.

13. Král M, Vyhnánková V, Študent V et al. Genetické riziko karcinomu prostaty. Ces Urol 2010; 14(3): 139– 147.

14. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000; 38(1): 59– 85.

15. Rosenkrantz AB, Mussi TC, Borofsky MS et al. 3.0 T multiparametric prostate MRI using pelvic phased‑ array coil: utility for tumor detection prior to bio­psy. Urol Oncol 2013; 31(8): 1430– 1435. doi: 10.1016/ j.urolonc.2012.02.018.

16. Roethke M, Anastasiadis AG, Lichy M et al. MRI‑ guided prostate bio­psy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS bio­psy. World J Urol 2012; 30(2): 213– 218. doi: 10.1007/ s00345‑ 011‑ 0675‑ 2.

17. Bělohlávek O, Jarolím L. Zobrazení karcinomu prostaty metodami nukleární medicíny. Ces Urol 2012; 16(4): 205– 213.

18. Afshar‑ Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a (68)Ga‑ labelled PSMA ligand and (18)F‑ choline‑based PET/ CT for the dia­gnosis of recurrent prostate cancor. Eur J Nucl Med Mol Imaging 2014; 41(1): 11– 20. doi: 10.1007/ s00259‑ 013‑ 2525‑ 5.

19. Eastham JA, Riedel E, Scardino PT et al. Variation of serum prostate‑ specific antigen levels: an evaluation of year‑ to‑year fluctuations. JAMA 2003; 289(20): 2695– 2700.

20. Čermák A, Marečková N, Pacík D. Infectious complications of prostate bio­psy: the changes in antibio­tics resistance patterns –  the review of 5 years period. J Urol 2010, 183 (4 Suppl): 817– 818.

21. Čermák A, Marečková N, Karmašová K et al. Antibio­tic resistance changes in infection following transrectal ultrasound guided prostate bio­psy –  review of 5 years period. Eur Urol 2010; 9 (2 Suppl): 82–83.

22. Čermák A, Pacík D. Transrektální ultrazvukem vedené bio­psie prostaty. Urol List 2007; 5(4): 22– 29.

23. Pacík D, Páč L, Čermák A et al. Výzkum senzitivní inervace parenchymu prostaty se zaměřením na možnost ovlivnění bolestivého vjemu při bio­psii prostaty. Ces Urol 2011; 15 (Suppl 2): 41.

24. Jones JS, Ulchaker JC, Nelson D et al. Periprostatic local anesthesia eliminates pain of office‑based trans­rectal prostate bio­psy. Prostate Cancer Prostatic Dis 2003; 6(1): 53– 55.

25. Borboroglu PG, Comer SW, Riffenburgh RH et al. Extensive repeat transrectal ultrasound guided prostate bio­psy in patients with previous benign sextant bio­psies. J Urol 2000; 163(1): 158– 162.

26. Djavan B, Remzi M, Schulman CC et al. Repeat prostate bio­psy: who, how and when? A review. Eur Urol 2002; 42(2): 93– 103.

27. Čermák A. Biopsie prostaty –  současná strategie, kde, kolik, jak odebírat vzorky? In: Karcinom prostaty od A do Z. Brno: Urologická klinika FNB 2011; 7.

28. Jones JS, Zippe CZ. Office‑based prostate bio­psy. Local anesthesia and strategy to improve cancer detection. 99th Annual Meeting AUA 2004; Postgrad Course: 7.

29. Loeb S, Carter HB, Berndt SI et al. Complications after prostate bio­psy: data from SEER‑ Medicare. J Urol 2011; 186(5): 1830– 1834. doi: 10.1016/ j.juro.2011.06.057.

30. NCCN clinical practice guidelines in oncology. Prostate cancer early detection. NCCN Practice GuidelinesTM 2012; version: 2.2012: 15.

31. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate‑ cancer screening trial. N Engl J Med 2009; 360(13): 1310– 1319. doi: 10.1056/ NEJMoa0810696.

32. Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate‑ cancer mortality in a randomized European study. N Engl J Med 2009; 360(13): 1320– 1328. doi: 10.1056/ NEJMoa0810084.

33. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Göteborg randomised population‑-bas­ed prostate‑ cancer screening trial. Lancet Oncol 2010; 11(8): 725– 732. doi: 10.1016/ S1470‑ 2045(10)70146‑ 7.

34. Pacík D. Karcinom prostaty pro praktického onkologa, urologa i rodinného lékaře. 1. ed. Praha: We Make Media s. r. o. 2007.

35. Belej K. Screening karcinomu prostaty, Onkologie 2009; 3(6): 351– 356.

36. Heidenreich A, Bastian PJ, Bellmunt J et al. Guidelines on prostate cancer. European Association of Urology 2013. Available from: http:/ / www.uroweb.org/ gls/ pdf/ 09_Prostate_Cancer_LR.pdf.

Labels
Paediatric urologist Urology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account